HS-20093, AN INVESTIGATIONAL B7-H3 TARGETED ANTIBODY-DRUG CONJUGATE, DEMONSTRATES ENCOURAGING RESULTS IN RELAPSED OR REFRACTORY EXTENSIVE-STAGE SMALL-CELL LUNG CANCER（UPDATES FROM ARTEMIS-001 PHASE I TRIAL AT WCLC 2024）
Shanghai, September 9, 2024, Hansoh Pharmaceutical Group Company Limited is pleased to announce updates from the ongoing Phase I ARTEMIS-001 trial evaluating the safety and efficacy of the B7-H3-targeted antibody-drug conjugate HS-20093 (also known as GSK5764227 or GSK’227) in patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy (relapsed or refractory). The dose escalation and expansion trial showed a 61.3% (n=31) and 50.0% (n=22) overall response rate (ORR) and median PFS 5.9months (n=31）and 7.3 months (n=22) in patients receiving 8.0 mg/kg and 10.0 mg/kg of HS-20093 respectively as of data cutoff of June 30, 2024. These data are presented today at the World Conference on Lung Cancer (WCLC) 2024 (7-10 September) in San Diego, California, USA, as an oral presentation.
Eliza Sun, Executive Director of Board, Hansoh Pharmaceutical Group, said: “We are excited about the encouraging results presented at the World Conference on Lung Cancer evaluating HS-20093 in this very difficult to treat patient population. These results, along with our other ongoing trials evaluating HS-20093, continue to further our confidence in bringing this investigational agent forward as a potentially transformative treatment option for patients with unmet needs.”
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “Patients with ES-SCLC face a poor prognosis, with limited treatment options and a significant need for new therapies. These data, which supported GSK’s recent Breakthrough Therapy Designation from the US Food and Drug Administration, represent promising early clinical evidence of the potential for GSK’227 in relapsed or refractory ES-SCLC and support our plans to proceed into phase I/II clinical trials this year.”
The safety and tolerability profile of HS-20093 in patients with ES-SCLC mainly included hematologic and gastrointestinal events. Grade ≥3 treatment-related adverse events (with incidence ≥10%) were neutrophil count decreased (39.3%), white blood cell count decreased (33.9%), lymphocyte count decreased (25.0%), platelet count decreased (17.9%), and anemia (16.1%).
About ES-SCLC
Lung cancer is one of the most common cancers worldwide. ES-SCLC is an aggressive and difficult-to-treat cancer with limited treatment options. More than two thirds of the patients with SCLC are diagnosed with ES-SCLC and the 5-year survival rate is approximately 3%.
ABOUT HS-20093
HS-20093 is a novel B7-H3-targeted antibody-drug conjugate (ADC) composed of a fully-humanized anti-B7-H3 monoclonal antibody covalently linked to topoisomerase inhibitor (TOPOi) payload and being developed for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumors in multiple phase I and II clinical studies in China.
On December 20, 2023, the Group entered into the License Agreement with GSK, pursuant to which GSK obtained an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture and commercialize HS-20093 (also known as GSK’227). GSK’s global Phase I trials for GSK’227 are set to begin this year.
ABOUT ARTEMIS-001
ARTEMIS-001 （NCT05276609） is an open-label, multi-center, dose-escalation and expansion, phase I study in adult participants with locally advanced or metastatic solid tumors, consisting of a dose escalation stage (Phase Ia) and a dose expansion stage (Part Ib).
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
